• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    8/14/23 1:35:22 PM ET
    $APLS
    $BSX
    $CVS
    $DOCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $APLS alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    JNJ CALL TRADE BEARISH 09/15/23 $210.00 $26.0K 632.7K 33.3K
    MRNA CALL SWEEP BEARISH 08/18/23 $100.00 $35.8K 903 1.6K
    APLS CALL TRADE BULLISH 06/21/24 $30.00 $169.8K 1.0K 1.0K
    PFE PUT SWEEP BEARISH 09/15/23 $37.50 $29.3K 20.4K 808
    BSX PUT SWEEP BULLISH 01/19/24 $47.00 $55.0K 3.4K 500
    CVS CALL TRADE BULLISH 01/19/24 $80.00 $28.1K 6.6K 445
    ZBH CALL SWEEP BEARISH 09/15/23 $130.00 $27.7K 608 432
    SAVA PUT SWEEP BEARISH 11/17/23 $22.50 $95.1K 2.2K 370
    RETA PUT SWEEP BEARISH 11/17/23 $170.00 $119.1K 750 311
    DOCS PUT TRADE BULLISH 01/19/24 $22.50 $48.7K 578 211

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For JNJ (NYSE:JNJ), we notice a call option trade that happens to be bearish, expiring in 32 day(s) on September 15, 2023. This event was a transfer of 2000 contract(s) at a $210.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $13.0 per contract. There were 632748 open contracts at this strike prior to today, and today 33326 contract(s) were bought and sold.

    • Regarding MRNA (NASDAQ:MRNA), we observe a call option sweep with bearish sentiment. It expires in 4 day(s) on August 18, 2023. Parties traded 200 contract(s) at a $100.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $35.8K, with a price of $179.0 per contract. There were 903 open contracts at this strike prior to today, and today 1640 contract(s) were bought and sold.

    • Regarding APLS (NASDAQ:APLS), we observe a call option trade with bullish sentiment. It expires in 312 day(s) on June 21, 2024. Parties traded 124 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $169.8K, with a price of $1370.0 per contract. There were 1016 open contracts at this strike prior to today, and today 1017 contract(s) were bought and sold.

    • For PFE (NYSE:PFE), we notice a put option sweep that happens to be bearish, expiring in 32 day(s) on September 15, 2023. This event was a transfer of 180 contract(s) at a $37.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $29.3K, with a price of $163.0 per contract. There were 20446 open contracts at this strike prior to today, and today 808 contract(s) were bought and sold.

    • For BSX (NYSE:BSX), we notice a put option sweep that happens to be bullish, expiring in 158 day(s) on January 19, 2024. This event was a transfer of 500 contract(s) at a $47.00 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $55.0K, with a price of $110.0 per contract. There were 3474 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold.

    • For CVS (NYSE:CVS), we notice a call option trade that happens to be bullish, expiring in 158 day(s) on January 19, 2024. This event was a transfer of 100 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $28.1K, with a price of $281.0 per contract. There were 6682 open contracts at this strike prior to today, and today 445 contract(s) were bought and sold.

    • For ZBH (NYSE:ZBH), we notice a call option sweep that happens to be bearish, expiring in 32 day(s) on September 15, 2023. This event was a transfer of 333 contract(s) at a $130.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.7K, with a price of $82.0 per contract. There were 608 open contracts at this strike prior to today, and today 432 contract(s) were bought and sold.

    • Regarding SAVA (NASDAQ:SAVA), we observe a put option sweep with bearish sentiment. It expires in 95 day(s) on November 17, 2023. Parties traded 160 contract(s) at a $22.50 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $95.1K, with a price of $594.0 per contract. There were 2275 open contracts at this strike prior to today, and today 370 contract(s) were bought and sold.

    • Regarding RETA (NASDAQ:RETA), we observe a put option sweep with bearish sentiment. It expires in 95 day(s) on November 17, 2023. Parties traded 361 contract(s) at a $170.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $119.1K, with a price of $330.0 per contract. There were 750 open contracts at this strike prior to today, and today 311 contract(s) were bought and sold.

    • For DOCS (NYSE:DOCS), we notice a put option trade that happens to be bullish, expiring in 158 day(s) on January 19, 2024. This event was a transfer of 199 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $48.7K, with a price of $245.0 per contract. There were 578 open contracts at this strike prior to today, and today 211 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLS
    $BSX
    $CVS
    $DOCS

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Zimmer Biomet Holdings Inc.
    $ZBH
    2/20/2026Mkt Perform
    William Blair
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Doximity Inc.
    $DOCS
    2/9/2026$34.00Hold → Buy
    Canaccord Genuity
    Doximity Inc.
    $DOCS
    2/6/2026$40.00Underweight → Neutral
    Analyst
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    More analyst ratings

    $APLS
    $BSX
    $CVS
    $DOCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Zimmer Biomet

    William Blair initiated coverage of Zimmer Biomet with a rating of Mkt Perform

    2/20/26 8:25:46 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $APLS
    $BSX
    $CVS
    $DOCS
    SEC Filings

    View All

    SEC Form PRE 14A filed by Boston Scientific Corporation

    PRE 14A - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    3/6/26 4:55:47 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Apellis Pharmaceuticals Inc.

    8-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

    3/2/26 7:05:19 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-4 filed by Boston Scientific Corporation

    S-4 - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    2/27/26 4:35:50 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $APLS
    $BSX
    $CVS
    $DOCS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $BSX
    $CVS
    $DOCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

    Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig (PF-07275315) was well-tolerated with a favorable safety profile Tilrekimig has the potential to be a first-in-class, once-monthly trispecific antibody targeting interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP) for multiple chronic Type 2 (Th2) inflammatory conditions including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD) Based on encouraging results, Pfizer plans to accelerate tilrekimig to Phase 3 development, with a pi

    3/9/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology

    MARLBOROUGH, Mass., March 6, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host an investor event and live webcast on Saturday, March 28, 2026, at 6:30 p.m. ET / 5:30 p.m. CT to discuss key clinical data presented earlier that day at the 75th Annual Scientific Session of the American College of Cardiology. The event will be hosted by Dr. Kenneth Stein, senior vice president and global chief medical officer, Dr. Brad Sutton, chief medical officer, AF solutions and Dr. Michael R. Jaff, vice president and chief medical officer, vascular therapies. The live web

    3/6/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

    Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression–free survival and overall survival versus standard of care regimens83.3% of patients were alive at three years, indicating durable clinical benefitHORSHAM, Pa., March 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteaso

    3/5/26 3:55:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $BSX
    $CVS
    $DOCS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $BSX
    $CVS
    $DOCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 10% to 65,782 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/6/26 4:24:57 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 12% to 56,998 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/6/26 4:21:25 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP & Controller Damico Jennifer B. was granted 21,719 shares and covered exercise/tax liability with 826 shares, increasing direct ownership by 174% to 32,934 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    3/5/26 5:27:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $BSX
    $CVS
    $DOCS
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLS
    $BSX
    $CVS
    $DOCS
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of

    3/2/26 4:30:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter

    2/25/26 1:00:00 PM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitabilityManagement to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Feb. 24, 2026 (G

    2/24/26 7:05:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $BSX
    $CVS
    $DOCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Doximity Inc.

    SC 13G/A - Doximity, Inc. (0001516513) (Subject)

    11/14/24 5:22:01 PM ET
    $DOCS
    EDP Services
    Technology